Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hemangiosarcoma × RNA, Messenger × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangiosarcoma 1

Interventions

pembrolizumab 3 durvalumab 3 Paclitaxel 3 Standard of Care 2 Nivolumab 2 Doxorubicin 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trebananib 1 trastuzumab duocarmazine 1 talazoparib 1 sintilimab 1 selinexor 1 sarilumab 1 regorafenib 1 pexidartinib 1 pertuzumab 1 peginterferon alfa-2a 1 pazopanib 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 eribulin 1 dostarlimab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡